Fig. 7

Knockdown of foxg1 exacerbates MPTP-induced PD-like symptoms in mice. A Experimental flow chart. Mice were injected with foxg1 AAVs into the midbrain 30 days prior to the experiment (green indicates midbrain astrocytes marked with GFAP, and red indicates the injected adenovirus, with a scale bar of 50 μm). Approximately 23 days later, mice were intraperitoneally injected with CB2R agonist JWH133 for 7 consecutive days. Subsequently, mice were subcutaneously injected with MPTP for 5 consecutive days, and JWH133 was also injected during these 5 days. Behavioral and biological tests of mice were performed thereafter. B The trajectory of the mice in the open field test, with distance traveled and time shown in C and D (n = 10), respectively. E, F Time recorded for each mouse in the rotarod test and pole test, respectively (n = 10). G Immunohistochemistry staining for TH-positive neurons in the midbrain of mice (scale bar, 200 μm), with stereological counts shown in H (n = 5). I Immunofluorescence detection of activated astrocytes in the midbrain of mice using GFAP as a marker (scale bar, 200 μm in the top panel, 100 μm in the bottom panel), with fluorescence quantification shown in J (n = 4). K, L Western blot detection of TH expression in midbrain and corresponding statistical data (n = 3). NS means not significant, ^*P < 0.05, ^**P < 0.01, ^***P < 0.001 compared with the corresponding group, as determined by the one-way ANOVA